Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1994 Jun;49(6):549–553. doi: 10.1136/thx.49.6.549

Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices.

M Hindle 1, H Chrystyn 1
PMCID: PMC474941  PMID: 8016791

Abstract

BACKGROUND--Inhalation aids do not require coordination between actuation of a metered dose inhaler (MDI) with inspiration and reduce oropharyngeal impaction. The delivery of salbutamol to the lung and systemic availability following inhalation with three commonly used spacers and an open mouth technique have been evaluated using a simple noninvasive technique based on urinary excretion 30 minutes and 24 hours after the dose. METHODS--Ten healthy subjects inhaled, on randomised study days, 4 x 100 micrograms from a Ventolin MDI and, subsequently, with the aid of a Volumatic, Bricanyl Spacer, and Nebuhaler spacer device. In addition, an open mouth inhaler technique was evaluated. Urine samples were collected 0-30 minutes and 0.5-24 hours after inhalation. From these samples the relative bioavailability to the lung (urinary salbutamol excretion 30 minutes after dosing) and the systemic bioavailability of the dose (24 hour urinary excretion of salbutamol and its metabolite) for each inhalation method was obtained. RESULTS--The mean (SD) urinary excretion of salbutamol 30 minutes after inhalation using the MDI alone and with the Volumatic, Bricanyl Spacer, Nebuhaler, and open mouth technique was 2.83 (0.78)%, 3.37 (0.69)%, 4.09 (0.91)%, 4.34 (1.60)%, and 3.49 (0.98)%, respectively, expressed as a percentage of the nominal dose. The nebuhaler and Bricanyl Spacer spacer devices were found to increase the relative bioavailability of salbutamol to the lung compared with the MDI alone. Compared with the MDI the inhalation aid increases were much greater than the intra-individual variability of the urinary excretion method. In 11 individuals who each repeated the same inhalation procedure on four separate occasions, the mean (SD) coefficient of variation was 8.24 (2.36)%. The mean (SD) 24 hour urinary excretion of salbutamol and its metabolites was 26.6 (6.79), 27.0 (7.95), and 55.6 (9.74)% of the salbutamol dose for the Volumatic, Nebuhaler, and MDI, respectively. Similar values following the open mouth method and Bricanyl Spacer were 48.9 (10.97)% and 43.8 (11.57)%. These values, representing the systemic availability of the inhaled dose, were lower when inhaling with the aid of the Volumatic and Nebuhaler than inhalation from the MDI alone. CONCLUSIONS--Spacer devices improve pulmonary bioavailability of salbutamol and reduce the systemically available dose.

Full text

PDF
549

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bloomfield P., Crompton G. K., Winsey N. J. A tube spacer to improve inhalation of drugs from pressurised aerosols. Br Med J. 1979 Dec 8;2(6203):1479–1479. doi: 10.1136/bmj.2.6203.1479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chapman B. J., Crompton G. K. Comparison of terbutaline via the Nebuhaler and salbutamol via the Volumatic: theory and practice. Eur Respir J. 1990 May;3(5):584–585. [PubMed] [Google Scholar]
  3. Chrystyn H. Standards for bioequivalence of inhaled products. Clin Pharmacokinet. 1994 Jan;26(1):1–6. doi: 10.2165/00003088-199426010-00001. [DOI] [PubMed] [Google Scholar]
  4. Crompton G. K. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis Suppl. 1982;119:101–104. [PubMed] [Google Scholar]
  5. Cyr T. D., Graham S. J., Li K. Y., Lovering E. G. Low first-spray drug content in albuterol metered-dose inhalers. Pharm Res. 1991 May;8(5):658–660. doi: 10.1023/a:1015825311750. [DOI] [PubMed] [Google Scholar]
  6. Hindle M., Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol. 1992 Oct;34(4):311–315. doi: 10.1111/j.1365-2125.1992.tb05921.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hindle M., Newton D. A., Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax. 1993 Jun;48(6):607–610. doi: 10.1136/thx.48.6.607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Keeley D. Large volume plastic spacers in asthma. BMJ. 1992 Sep 12;305(6854):598–599. doi: 10.1136/bmj.305.6854.598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. König P. Spacer devices used with metered-dose inhalers. Breakthrough or gimmick? Chest. 1985 Aug;88(2):276–284. doi: 10.1378/chest.88.2.276. [DOI] [PubMed] [Google Scholar]
  10. Melchor R., Biddiscombe M. F., Mak V. H., Short M. D., Spiro S. G. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax. 1993 May;48(5):506–511. doi: 10.1136/thx.48.5.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Munch E. P., Hidinger K. G., Weeke B. Bronchodilation of terbutaline in small doses from a 750 ml spacer. A cumulative dose-response study. Allergy. 1983 Oct;38(7):487–491. doi: 10.1111/j.1398-9995.1983.tb02357.x. [DOI] [PubMed] [Google Scholar]
  12. Newman S. P., Millar A. B., Lennard-Jones T. R., Morén F., Clarke S. W. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax. 1984 Dec;39(12):935–941. doi: 10.1136/thx.39.12.935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Paterson I. C., Crompton G. K. Use of pressurised aerosols by asthmatic patients. Br Med J. 1976 Jan 10;1(6001):76–77. doi: 10.1136/bmj.1.6001.76-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Prahl P., Jensen T. Decreased adreno-cortical suppression utilizing the Nebuhaler for inhalation of steroid aerosols. Clin Allergy. 1987 Sep;17(5):393–398. doi: 10.1111/j.1365-2222.1987.tb02031.x. [DOI] [PubMed] [Google Scholar]
  15. Rivlin J., Mindorff C., Reilly P., Levison H. Pulmonary response to a bronchodilator delivered from three inhalation devices. J Pediatr. 1984 Mar;104(3):470–473. doi: 10.1016/s0022-3476(84)81119-1. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES